Prof. Dr. Jessica Hassel, senior physician and section head of Dermatooncology at Heidelberg University Hospital/NCT Heidelberg, presented new findings regarding the survival boosting effect of Tebentafusp at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
It was recently discovered in a randomized phase 3 trial by Piperno-Neumann, Hassel, Rutkowski, et al. that Immunocore’s bispecific fusion protein Tebentafusp (IMCgp100) improves overall survival in advanced uveal melanoma. Tebentafusp redirects T cells to the uveal melanoma metastases, thereby enabling an immune attack.
Further information:
https://www.onclive.com/view/frontline-tebentafusp-significantly-improves-os-in-metastatic-uveal-melanoma
https://cancerdiscovery.aacrjournals.org/content/early/2021/04/09/2159-8290.CD-NB2021-0333
vom 14.04.2021
Uveal melanoma: Prof. Jessica Hassel presents results of a phase III clinical trial at the annual meeting of the American Association for Cancer Research
